1. Select miRNA symbol:

2. Select Dataset: Compare

Survival options

Survival	OS (n=2514)
Split patients by	--none--lower quartilelower tertilemedianupper tertileupper quartile
	Auto select best cutoff
	Trichotomization: --none--T1 vs T3Q1 vs Q4

Follow up threshold:	all2 months4 months6 months12 months18 months24 months30 months36 months48 months60 months120 months180 months240 months
Censore at threshold:
Compute median survival:
Export plot data as text:

Restrict analysis to subtypes...

ER status:	IHC:	allER positive (n=1523)ER negative (n=591)
	Gene chip:	allER positive (n=979)ER negative (n=283)
PGR status:	IHC:	allPGR positive (n=434)PGR negative (n=337)
HER2 status:	IHC:	allHER2 negative (n=683)HER2 positive (n=740)
	Gene chip:	allHER2 negative (n=1105)HER2 positive (n=157)

Molecular subtype:

allTNBC (n=300)luminal A(ER+HER2-KI67-) (n=546)luminal B (n=433)HER2+ER- (n=105)

---

Grade:	all1 (n=108)2 (n=510)3 (n=774)
Lymph node status:	allpositive (n=954)negative (n=1023)

Restrict analysis to selected cohorts...

	systemically untreated patients:		include (n=199)exclude (n=1063)
	systemically treated patients:
ER-positive endocrine therapy:			any (n=1262)include all (n=779)exclude all (n=483)
chemotherapy:			anyinclude all (n=280)exclude all (n=982)
	do not use cohorts

Compare datasets

METABRIC: long follow-up (median: 94 months), average characteristics (78% ER positive, 12% HER2 positive), treatment data available for this dataset only!
TCGA: very short follow-up (median only 25 months), no grade.
GSE40267: almost exclusively ER negative patients (92%).
GSE19783: nodal status not available, 38% ER negative, high proportion of HER2 positive patients (18%).

n = number of patients with available clinical data

Loading...

Please note: the generated p value does not include correction for multiple hypothesis testing by default.

Please kindly cite our paper to support further development: Lanczky A, Nagy A, Bottai G, Munkacsy G, Paladini L, Szabo A, Santarpia L, Gyorffy B. miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2,178 breast cancer patients, Breast Cancer Res Treat. 2016;160(3):439-446.